Eli Lilly and Company

Daniel Jon Sall

Jolie Anne Bastian

Ho-Shen Lin

John Michael Morin, Jr

Gerald Floyd Smith

Matthew Joseph Fisher

Michael Dean Kinnick

Jason Scott Sawyer

Richard Waltz Harper

Michael Robert Wiley

Michael Enrico Richett

Kumiko Takeuchi

Jefferson Ray McCowan

Minsheng Zhang

Theo Schotten

Alan David Palkowitz

Michael Lyle Denney

Nickolay Y Chirgadze

Douglas Wade Beight

Robert Theodore Vasileff

Jeffrey Daniel Cohen

Cynthia Darshini Jesudason

Joseph A Jakubowski

John Arnold Werner

Almudena Rubio

Allen D Kline

Anne Marie Happ

Marshall A Skelton

Robert J Foglesong

Mary George Johnson

Freddie Craig Stevens

Gerd Ruehter

Michael P Lynch

Nicholas J Bach

Wolfgang Stenzel

Edward David Mihelich

Robert T Shuman

Michael J Martinelli

Philip Arthur Hipskind

Valentine Joseph Klimkowski

Kenneth Jeff Thrasher

Vincent Patrick Rocco

Jennifer Marie Tinsley

Michael Paal

Stephen Clinton Young

Edward C R Smith

Patrick Gianpietro Spinazze

Kenneth Lee Hauser

Don Richard Finley

Andrew Michael Ratz

Todd Jonathan Kohn

Kenneth James Ruterbories

John Xiaoqiang He

Takako Wilson (nee Takakuwa)

Jennifer Anne McMahon

William George Trankle

Gerd Reuhter

Christopher William Murray

Robert D Dillard

James Robert Henry

Michael LeRoy Phillips

John E Toth

Benjamin Alan Anderson

William Thomas McMillen

Stuart Donald Jones

Susan Elizabeth Draheim

Tulio Suarez

Shawn Christopher Miller

Joshua Ryan Clayton

Gaiying Zhao

Nancy Kay Harn

Gerd Ruhter

Gary A Hite

Richard Walter Schevitz

John Mcneill McGill, Iii

Rushad Eruch Karanjawala

Britta Evers

Julia Marie Clay

Michelle Lee Thompson

Richard James Loncharich

Jiehao Chen

Bradley Earl Reaman

David Andrew Coates

Russell Dean Stucky

Karen Lynn Lobb

John Walter Liebeschuetz

David Michael Remick

Miles Goodman Siegel

Timothy Andrew Woods

Jeffrey Thomas Mullaney

Takako Wilson

Kenneth Dean Kurz

John David Jandzinski

Gerd R&uuml;hter

Jolie Ann Bastian

Todd Johnathan Kohn

John Andrew Buben

Robert B Rothenberger

John M Morin

Steven Douglas Hiscock

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

Selective estrogen receptor degraders

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, —CF, or —CH, and the other is hydrogen, and methods for their use are provided.

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, &#x2014;CF, or &#x2014;CH, and the other is hydrogen, and methods for their use are provided.

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. 

1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer

The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.

Pyrazolylaminobenzimidazole derivatives as JAK inhibitors

The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds. 

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

2,3-dihydro-1H-indole compounds

The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C&#x2014;Ror N; Ris hydrogen, fluoro or cyano; Ris formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; Ris methyl or trifluoromethyl; Ris pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; Ris trifluoromethyl or methylsulfonyl; Ris hydrogen or methyl; and R, R, R, Rand Rare independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R, R, R, Rand Rare hydrogen useful in the treatment of cancer. 

Tetrasubstituted pyridazine hedgehog pathway antagonists

The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.

Tetrasubstituted pyridazines hedgehog pathway antagonists

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. 

Disubstituted phthalazine hedgehog pathway antagonists

Compounds of formula (I) in which R, R, R, n and Xhave the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders

Compounds of formula (I) in which R, R, Rand R, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Chemical compounds

Compounds of formula (I) in which R, Rand Xhave the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Growing community of inventors

Greenwood, IN, United States of America

Daniel Jon Sall